Abstract
The present disclosure relates to the treatment and prevention of impaired cognitive function, cognitive decline and/or dementia or signs of cerebral neurodegeneration in a subject with diabetes mellitus by administration of a pharmaceutical composition comprising a compound capable of lowering the level or amount of copper in the hippocampus, or elsewhere in the brain, of the subject.
| Original language | English |
|---|---|
| Patent number | WO2023203378 (A1) |
| Publication status | Published - 26 Oct 2023 |